Form 4: AbbVie CEO Richard Gonzalez Reports Stock Transactions
SEC Form 4 Filing
AbbVie's Chairman and CEO, Richard Gonzalez, reported the acquisition and disposition of company stock on February 28, 2024.
Summary
- Richard A. Gonzalez, Chairman and CEO of AbbVie Inc., filed a Form 4 with the SEC on March 1, 2024.
- The report details changes in his beneficial ownership of AbbVie common stock.
- On February 28, 2024, Gonzalez acquired 110,249 shares through a transaction exempt from reporting under Section 16.
- On the same day, he sold 138,616 shares at a weighted average price of $177.27, with individual sales ranging from $177.25 to $177.56.
- Following these transactions, Gonzalez directly owns 519,099 shares of AbbVie common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company executive, with neutral sentiment.
Industry Context
Form 4 filings are standard practice for corporate insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The stock sale by the CEO may be perceived negatively by some shareholders, but it is a common practice and doesn't necessarily indicate a negative outlook for the company.
Key Dates
| Date | Description |
|---|---|
| 02/28/2024 | Date of stock acquisition and disposition. |
| 03/01/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.